129 related articles for article (PubMed ID: 14514352)
1. Putative role of membranes in the HIV fusion inhibitor enfuvirtide mode of action at the molecular level.
Veiga S; Henriques S; Santos NC; Castanho M
Biochem J; 2004 Jan; 377(Pt 1):107-10. PubMed ID: 14514352
[TBL] [Abstract][Full Text] [Related]
2. HIV fusion inhibitor peptide T-1249 is able to insert or adsorb to lipidic bilayers. Putative correlation with improved efficiency.
Veiga AS; Santos NC; Loura LM; Fedorov A; Castanho MA
J Am Chem Soc; 2004 Nov; 126(45):14758-63. PubMed ID: 15535700
[TBL] [Abstract][Full Text] [Related]
3. The improved efficacy of Sifuvirtide compared with enfuvirtide might be related to its selectivity for the rigid biomembrane, as determined through surface plasmon resonance.
Cao P; Dou G; Cheng Y; Che J
PLoS One; 2017; 12(2):e0171567. PubMed ID: 28207776
[TBL] [Abstract][Full Text] [Related]
4. Non-peptide entry inhibitors of HIV-1 that target the gp41 coiled coil pocket.
Stewart KD; Huth JR; Ng TI; McDaniel K; Hutchinson RN; Stoll VS; Mendoza RR; Matayoshi ED; Carrick R; Mo H; Severin J; Walter K; Richardson PL; Barrett LW; Meadows R; Anderson S; Kohlbrenner W; Maring C; Kempf DJ; Molla A; Olejniczak ET
Bioorg Med Chem Lett; 2010 Jan; 20(2):612-7. PubMed ID: 20004576
[TBL] [Abstract][Full Text] [Related]
5. Design of a novel HIV-1 fusion inhibitor that displays a minimal interface for binding affinity.
Oishi S; Ito S; Nishikawa H; Watanabe K; Tanaka M; Ohno H; Izumi K; Sakagami Y; Kodama E; Matsuoka M; Fujii N
J Med Chem; 2008 Feb; 51(3):388-91. PubMed ID: 18197613
[TBL] [Abstract][Full Text] [Related]
6. Sifuvirtide screens rigid membrane surfaces. establishment of a correlation between efficacy and membrane domain selectivity among HIV fusion inhibitor peptides.
Franquelim HG; Loura LM; Santos NC; Castanho MA
J Am Chem Soc; 2008 May; 130(19):6215-23. PubMed ID: 18410103
[TBL] [Abstract][Full Text] [Related]
7. Molecular dynamics simulation of HIV fusion inhibitor T-1249: insights on peptide-lipid interaction.
Martins do Canto AM; Palace Carvalho AJ; Prates Ramalho JP; Loura LM
Comput Math Methods Med; 2012; 2012():151854. PubMed ID: 22675399
[TBL] [Abstract][Full Text] [Related]
8. Molecular dynamics simulations of T-20 HIV fusion inhibitor interacting with model membranes.
do Canto AM; Carvalho AJ; Ramalho JP; Loura LM
Biophys Chem; 2011 Dec; 159(2-3):275-86. PubMed ID: 21868145
[TBL] [Abstract][Full Text] [Related]
9. T-20 and T-1249 HIV fusion inhibitors' structure and conformation in solution: a molecular dynamics study.
Martins Do Canto AM; Palace Carvalho AJ; Prates Ramalho JP; Loura LM
J Pept Sci; 2008 Apr; 14(4):442-7. PubMed ID: 18069719
[TBL] [Abstract][Full Text] [Related]
10. Decoding distinct membrane interactions of HIV-1 fusion inhibitors using a combined atomic force and fluorescence microscopy approach.
Franquelim HG; Gaspar D; Veiga AS; Santos NC; Castanho MA
Biochim Biophys Acta; 2013 Aug; 1828(8):1777-85. PubMed ID: 23500616
[TBL] [Abstract][Full Text] [Related]
11. Conjugation of cholesterol to HIV-1 fusion inhibitor C34 increases peptide-membrane interactions potentiating its action.
Hollmann A; Matos PM; Augusto MT; Castanho MA; Santos NC
PLoS One; 2013; 8(4):e60302. PubMed ID: 23565220
[TBL] [Abstract][Full Text] [Related]
12. Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition.
Ding X; Zhang X; Chong H; Zhu Y; Wei H; Wu X; He J; Wang X; He Y
J Virol; 2017 Sep; 91(18):. PubMed ID: 28659478
[TBL] [Abstract][Full Text] [Related]
13. Conjugation of a nonspecific antiviral sapogenin with a specific HIV fusion inhibitor: a promising strategy for discovering new antiviral therapeutics.
Wang C; Lu L; Na H; Li X; Wang Q; Jiang X; Xu X; Yu F; Zhang T; Li J; Zhang Z; Zheng B; Liang G; Cai L; Jiang S; Liu K
J Med Chem; 2014 Sep; 57(17):7342-54. PubMed ID: 25156906
[TBL] [Abstract][Full Text] [Related]
14. Heptad-repeat-2 mutations enhance the stability of the enfuvirtide-resistant HIV-1 gp41 hairpin structure.
Jenwitheesuk E; Samudrala R
Antivir Ther; 2005; 10(8):893-900. PubMed ID: 16430194
[TBL] [Abstract][Full Text] [Related]
15. Resistance to enfuvirtide, the first HIV fusion inhibitor.
Greenberg ML; Cammack N
J Antimicrob Chemother; 2004 Aug; 54(2):333-40. PubMed ID: 15231762
[TBL] [Abstract][Full Text] [Related]
16. A synthetic C34 trimer of HIV-1 gp41 shows significant increase in inhibition potency.
Nomura W; Hashimoto C; Ohya A; Miyauchi K; Urano E; Tanaka T; Narumi T; Nakahara T; Komano JA; Yamamoto N; Tamamura H
ChemMedChem; 2012 Feb; 7(2):205-8. PubMed ID: 22247043
[No Abstract] [Full Text] [Related]
17. Development of a novel fusion inhibitor against T-20-resistant HIV-1.
Oishi S; Ito S; Nishikawa H; Tanaka M; Ohno H; Otaka A; Izumi K; Kodama E; Matsuoka M; Fujii N
Adv Exp Med Biol; 2009; 611():389-91. PubMed ID: 19400237
[No Abstract] [Full Text] [Related]
18. Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy.
Zhu X; Zhu Y; Ye S; Wang Q; Xu W; Su S; Sun Z; Yu F; Liu Q; Wang C; Zhang T; Zhang Z; Zhang X; Xu J; Du L; Liu K; Lu L; Zhang R; Jiang S
Sci Rep; 2015 Aug; 5():13028. PubMed ID: 26286358
[TBL] [Abstract][Full Text] [Related]
19. Discontinuation of the clinical development of fusion inhibitor T-1249.
Martin-Carbonero L
AIDS Rev; 2004; 6(1):61. PubMed ID: 15168742
[No Abstract] [Full Text] [Related]
20. HIV-1 fusion inhibitor peptides enfuvirtide and T-1249 interact with erythrocyte and lymphocyte membranes.
Matos PM; Castanho MA; Santos NC
PLoS One; 2010 Mar; 5(3):e9830. PubMed ID: 20352107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
